Figure 4
The presence of any adverse lesion in patients with or without hyperdiploidy is associated with worse PFS and OS, within both the intensive and nonintensive pathways. Three patient groups were compared (group 1, HRD with no adverse lesion; group 2, HRD plus any adverse lesion; group 3, non-HRD with any adverse lesion) to analyze their PFS and OS depending on treatment pathway. (A-B) Analysis of PFS for patients through the intensive pathway (A) or nonintensive pathway (B). (C-D) Analysis of OS through the intensive pathway (C) or nonintensive pathway (D). Log-rank tests are calculated in pairwise comparisons. Note that the presence of HRD in patients with adverse lesions does not significantly improve outcome (compare group 2 vs 3). HRD, hyperdiploidy.

The presence of any adverse lesion in patients with or without hyperdiploidy is associated with worse PFS and OS, within both the intensive and nonintensive pathways. Three patient groups were compared (group 1, HRD with no adverse lesion; group 2, HRD plus any adverse lesion; group 3, non-HRD with any adverse lesion) to analyze their PFS and OS depending on treatment pathway. (A-B) Analysis of PFS for patients through the intensive pathway (A) or nonintensive pathway (B). (C-D) Analysis of OS through the intensive pathway (C) or nonintensive pathway (D). Log-rank tests are calculated in pairwise comparisons. Note that the presence of HRD in patients with adverse lesions does not significantly improve outcome (compare group 2 vs 3). HRD, hyperdiploidy.

Close Modal

or Create an Account

Close Modal
Close Modal